No Photo Available

Last Update

2015-11-21T00:00:00.000Z

This profile was last updated on .

Is this you? Claim your profile.

Wrong Kimme Hyrich?

Dr. Kimme L. Hyrich

Principal Investigator

British Society for Rheumatology Rheumatoid Arthritis Biologics Register

Get ZoomInfo Grow

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

British Society for Rheumatology Rheumatoid Arthritis Biologics Register

Background Information

Employment History

Manchester City Council

Professor of Epidemiology

The University of Manchester

Senior Lecturer In Rheumatic Disease Epidemiology

Manchester

Education

PhD

Web References (20 Total References)


Principal Investigators: Professor Wendy ...

www.inflammation-repair.manchester.ac.uk [cached]

Principal Investigators: Professor Wendy Thomson ; Dr Kimme Hyrich

...
Principal Investigator:Dr Kimme Hyrich
British Society for Rheumatology Rheumatoid Arthritis Biologics Register (the largest prospective observational study of the safety and clinical effectiveness of biologic agents), BSPAR Biologics Register, BILAG Biologics Register


Video: M-cubed Event Four (20 July 2013) (MHS - University of Manchester)

www.mhs.manchester.ac.uk [cached]

Dr Kimme Hyrich


Staff (Musculoskeletal Research Group - University of Manchester)

www.medicine.manchester.ac.uk [cached]

Kimme Hyrich Senior Lecturer in Rheumatic Disease Epidemiology kimme.hyrich@manchester.ac.uk


arc Epidemiology Unit: staff (Epidemiology Research Group - University of Manchester)

www.medicine.manchester.ac.uk [cached]

Kimme HyrichSenior Lecturer in Rheumatic Disease Epidemiologykimme.hyrich@manchester.ac.uk


The crude incidence rate of first ...

www.medpagetoday.com [cached]

The crude incidence rate of first MI was 35 (95% CI 30-40) per 10,000 patient-years among patients receiving TNF inhibitors compared with 56 (95% CI 46-73) among those receiving conventional synthetic DMARDs, according to Kimme L. Hyrich, MD, PhD, of the University of Manchester in England, and colleagues.

...
Therefore, to consider longer-term risks of MI, as well as the severity and mortality associated with cardiovascular events, Hyrich and colleagues analyzed data from the British Society for Rheumatology's Biologics Register and the Myocardial Ischemia National Audit Project for the years 2001 to 2010.
...
Hyrich and colleagues concluded, "Treatment with TNF inhibitor therapy for rheumatoid arthritis was associated with a reduced risk of MI over the medium term compared with synthetic DMARD therapy.
...
Hyrich disclosed relevant relationships with Pfizer and AbbVie.

Similar Profiles

Other People with this Name

Other people with the name Hyrich

Theresa Hyrich
Winnipeg School Division

Joe Hyrich
CH2M HILL Companies Ltd

Theresa Hyrich
Elmwood Community Schools

Cynthia Hyrich

Jolyn Hyrich
Stahl Peterbilt Inc

City Directory Icon

Browse ZoomInfo's Business Contact Directory by City

People Directory Icon

Browse ZoomInfo's
Business People Directory

Company Directory Icon

Browse ZoomInfo's
Advanced Company Directory